603456 Zhejiang Jiuzhou Pharmaceutical
- 16.66
- -0.84-4.80%
Zhejiang Jiuzhou Pharmaceutical News
Zhejiang Jiuzhou Pharmaceutical Completes Establishment of German Unit
Express News | Zhejiang Jiuzhou Pharmaceutical: Sold its 25% equity stake in Fangda (Suzhou) for 19.6 million yuan.
Zhejiang Jiuzhou Pharmaceutical (603456): The CDMO project pipeline maintains steady growth, awaiting industry recovery.
Event: In the first 24 hours, revenue reached 2.764 billion yuan (-15.07%), net income attributable to the parent company reached 0.475 billion yuan (-23.60%), and non-GAAP net income attributable to the parent company reached 0.468 billion yuan (-23.64%); single Q2
Zhejiang Jiuzhou Pharmaceutical (603456): The CDMO pipeline is becoming increasingly abundant, creating a platform for peptides and conjugation.
1H24 performance slightly lower than our expectations. The company announced 1H24 performance: revenue of 2.764 billion yuan, -15.07% year-on-year; net income attributable to mother of 0.475 billion yuan, -23.62% year-on-year; non-net income of 0.468 billion.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. 2024 Interim Report
Summary of the semi-annual report of Zhejiang Jiuzhou Pharmaceutical Co., Ltd. in 2024
Express News | Zhejiang Jiuzhou Pharmaceutical: net income in the first half of the year decreased by 23.62% year-on-year.
Zhejiang Jiuzhou Pharmaceutical (603456.SH): The net income for the first half of the year decreased by 23.62% to 0.475 billion yuan.
On August 26th, Jiuzhou Pharmaceutical (603456.SH) released its semi-annual report. During the reporting period, the company achieved revenue of 2.764 billion yuan, a decrease of 15.07% compared to the previous year. The net income attributable to the parent company was 0.475 billion yuan, a decrease of 23.62% compared to the previous year. During the reporting period, the company was honored with multiple awards, including being ranked in the top 20 CDAYO enterprises in the Chinese pharmaceutical CDMO industry in 2024, the top 100 companies in the Chinese pharmaceutical industry in 2023, and being recognized as a leading enterprise in the biomedical industry in Zhejiang Province.
Express News | Zhejiang Jiuzhou Pharmaceutical: The company achieved revenue of 2.764 billion yuan in the first half of 2024, a year-on-year decrease of 15.07%; net income of 0.475 billion yuan, a year-on-year decrease of 23.62%.
Zhejiang Jiuzhou Pharmaceutical (603456.SH): No drugs for the treatment of prostate.
Zhejiang Jiuzhou Pharmaceutical (603456.SH) stated on the investor interaction platform on August 21 that the company does not have drugs for the treatment of prostate.
Zhejiang Jiuzhou Pharmaceutical (603456.SH): No products related to monkeypox virus are available.
On August 15th, Gelunhui reported that zhejiang jiuzhou pharmaceutical (603456.SH) stated on the investor interaction platform that the company has no products related to monkeypox virus.
Zhejiang Jiuzhou Pharmaceutical (603456): Started with active pharmaceutical ingredient business, strong CDMO capabilities + extended development of preparations.
Zhejiang Jiuzhou Pharmaceutical started with specialty active pharmaceutical ingredients/intermediates, relying on years of technological accumulation and advantages in customer resource index, has achieved fruitful results in the CDMO business, and further expanded into the formulation and formulation CDMO business. Active pharmaceutical ingredient.
Two directors and executives of Zhejiang Jiuzhou Pharmaceutical (603456.SH) increased their shareholding by a total of 0.8327 million shares.
Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that as of the date of disclosure of the announcement, Director and CEO Mr. Mei Yi Jiang has accumulated an increase...
Zhejiang Jiuzhou Pharmaceutical (603456.SH): The plan for some directors and senior management to increase their shareholding in the company has been completed.
On July 23, Glonhui reported that as of the disclosure date of the announcement, Mr. Mei Yi will accumulate a shareholding of 643,300 shares, accounting for 0.0715% of the total share capital of the company, with a shareholding amount of 12.05 million yuan; Mr. Sha Yujie will accumulate a shareholding of 189,400 shares, accounting for 0.0211% of the total share capital of the company, with a shareholding amount of 3.02 million yuan. The shareholding plan is completed.
Zhejiang Jiuzhou Pharmaceutical (603456.SH): Okasipin tablets obtained pharmaceutical registration certificate.
Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that its controlling subsidiary, Zhejiang Jiuzhou Biomedical Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Oxcarbazepine Tablets issued by the National Medical Products Administration. Oxcarbazepine tablets are used to treat primary generalized tonic-clonic seizures and partial seizures with or without secondary generalized seizures.
Express News | Zhejiang Jiuzhou Pharmaceutical: Holding subsidiary obtains pharmaceutical registration certificate.
Zhejiang Jiuzhou Pharmaceutical (603456.SH) will distribute a cash dividend of 0.5 yuan per share for the year 2023 on July 4.
Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that the company will distribute the annual dividend for 2023 on July 4, 2024...
Zhejiang Jiuzhou Pharmaceutical (603456.SH): plans to cancel its subsidiaries Ruibo Life Sciences and Ruibo Europe.
On June 18th, Gelonhui reported that Zhejiang Jiuzhou Pharmaceutical (603456.SH) plans to cancel its subsidiaries, Zhejiang Ruibo Life Science and Technology Co., Ltd. (referred to as "Ruibo Life Science") and Raybow Europe Incorporated ApS (referred to as "Ruibo Europe"), and authorize the management to handle the cancellation matters.
Express News | Zhejiang Jiuzhou Pharmaceutical: Received approval for the listing application of chemical raw materials for methanesulfonic acid ruxolitinib.
Jiuzhou Pharmaceutical (603456.SH): Total cost of 99.89 million yuan to repurchase 0.64% of the joint stock company completed the repurchase
Gelonghui May 24 丨 Jiuzhou Pharmaceutical (603456.SH) announced that on May 23, 2024, the company completed this share repurchase. The company has actually repurchased 5,789,800 shares through centralized bidding transactions, accounting for 0.64% of the company's total share capital. The highest price of the repurchase transaction was 22.18 yuan/share, the lowest price was 15.11 yuan/share, and the total amount paid was RMB 99,893,380.10 (not including transaction fees).
Analysis
Price Target
No Data
No Data